购物车
- 全部删除
- 您的购物车当前为空
Uzansertib phosphate (INCB053914 phosphate) 是一种可口服的 ATP 竞争性泛-PIM 激酶抑制剂,对多种血液肿瘤细胞系具有广泛的抗增殖活性,对 PIM1、PIM2 和 PIM3 的 IC50分别为 0.24 、30 和 0.12 nM。
Uzansertib phosphate (INCB053914 phosphate) 是一种可口服的 ATP 竞争性泛-PIM 激酶抑制剂,对多种血液肿瘤细胞系具有广泛的抗增殖活性,对 PIM1、PIM2 和 PIM3 的 IC50分别为 0.24 、30 和 0.12 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 892 | 现货 | |
5 mg | ¥ 2,320 | 现货 | |
10 mg | ¥ 3,480 | 现货 | |
25 mg | ¥ 5,560 | 现货 | |
50 mg | ¥ 7,560 | 现货 | |
100 mg | ¥ 9,870 | 现货 |
产品描述 | Uzansertib phosphate (INCB053914 phosphate) is an orally active, ATP-competitive inhibitor of pan-PIM kinase(PIM1, PIM2, PIM3 with IC50s of 0.24 nM, 30 nM, 0.12 nM , respectively). |
靶点活性 | Pim2:30 nM, Pim3:0.12 nM, Pim1:0.24 nM |
体外活性 | INCB053914, a novel, potent, and selective adenosine triphosphate-competitive pan-PIM kinase inhibitor.?In vitro, INCB053914 inhibited proliferation and the phosphorylation of downstream substrates in cell lines from multiple hematologic malignancies. |
体内活性 | Effects were confirmed in primary bone marrow blasts from patients with acute myeloid leukemia treated ex vivo and in blood samples from patients receiving INCB053914 in an ongoing phase 1 dose-escalation study.?In vivo, single-agent INCB053914 inhibited Bcl-2-associated death promoter protein phosphorylation and dose-dependently inhibited tumor growth in acute myeloid leukemia and multiple myeloma xenografts.?Additive or synergistic inhibition of tumor growth was observed when INCB053914 was combined with selective PI3Kδ inhibition, selective JAK1 or JAK1/2 inhibition, or cytarabine. |
别名 | INCB053914 phosphate |
分子量 | 611.51 |
分子式 | C26H29F3N5O7P |
CAS No. | 2088852-47-3 |
Smiles | O=C(C1=NC(C2=C(F)C=CC=C2F)=C(F)C=C1)NC3=CN=C4C(CC[C@H]4O)=C3N5C[C@@H](N)[C@H](O)[C@@H](C)C5.O=P(O)(O)O |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||
溶解度信息 | DMSO: 5 mg/mL (8.18 mM), Sonication and heating are recommended. | |||||||||||||||
溶液配制表 | ||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容